Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation - Trial NCT01873352
Access comprehensive clinical trial information for NCT01873352 through Pure Global AI's free database. This Phase 3 trial is sponsored by Meshalkin Research Institute of Pathology of Circulation and is currently Completed. The study focuses on Atrial Fibrillation,Hypertension. Target enrollment is 302 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Meshalkin Research Institute of Pathology of Circulation
Timeline & Enrollment
Phase 3
Jun 20, 2013
Mar 01, 2019
Primary Outcome
AAD-free freedom from AF/atrial flutter/atrial tachycardia recurrence at least 30 seconds
Summary
The objective of this trial is to determine the role of renal sympathetic denervation in the
 prevention of atrial fibrillation (AF) recurrence in patients with hypertension for whom a
 catheter-based AF ablation procedure is planned. Patients will be randomized to either AF
 catheter ablation (usual therapy) or AF catheter ablation plus renal sympathetic denervation.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01873352
Non-Device Trial